Leadership Team

Iain has over 40 years' experience in the international life sciences and technology sectors and has held significant roles in multi-national companies including Sandoz, Hoffman La Roche, and Celltech Group plc. He has completed multiple financing transactions and turnarounds and has over 30 years' experience in cross-border management as a chairman and CEO. He has led and participated in eight Initial Public Offerings (IPOs) and has direct experience of M&A transactions in Europe, the USA and the Pacific Rim. Iain led the turnaround and re-structuring of several biotech companies including Ark Therapeutics, Redx Pharma, Silence Therapeutics and more recently, ReNeuron.

Alexandre was born in Ukraine, grew up in Georgia, and later studied mathematics, physics, chemistry, biochemistry, and biophysics at the Moscow Institute of Physics and Technology, all countries then being part of the USSR. In 1989, he was selected by the George Soros Foundation for the Oxford Scholarship, associated with St. Antony’s College, along with 20 top Soviet graduate students. He obtained his PhD in cell biology from University College, London (with the research-based at the Imperial Cancer Research Fund). He then spent six years at the Robert Wood Johnson Medical School-UMDNJ, NJ, as a research assistant funded by the Howard Hughes Medical Institute. Upon his return to England, he established his research laboratory at the Sir William Dunn School of Pathology, University of Oxford. He was a University Academic Fellow (Research Council UK) and a Senior Fellow of Exeter College, sponsored by Cancer Research UK, the Wellcome Trust, and The Medical Research Council. Alexandre is a Fellow of the Royal Society of Medicine.

Thomas has 30+ yrs in biotechnology and clinical diagnostic laboratory management with diverse strengths in logistics, manufacturing, and operations for both large and early-stage companies; Life Technologies, Expression Pathology, Cellectricon, OncoPlex Diagnostics and OpGen.

He was an early contributor and Vice President of Expression Pathology which, as COO, was transformed to a CAP/CLIA Diagnostic Laboratory (OncoPlex Diagnostics) offering unique clinical proteomic testing for oncology.

During his tenure with Life Technologies, Thomas led a multi-national team which created a $50MM+ custom oligonucleotide manufacturing segment creating capabilities and facilities in the US, UK, JP, NZ, HK and BR.

Paul joined the Company in September 2017 from e-Therapeutics plc, where he held the position of Financial Controller from 2012. Paul is a Chartered Accountant and was a Senior Manager at Deloitte, where he worked from 1996 until 2004. Following this, he worked in finance and operations management in the charitable and automotive sectors. He read Natural Sciences at St John's College, University of Cambridge.

Ewan has worked in Biotech for over 20 years, for several companies including Silicon Genetics Inc, Agilent Technologies, Thomson Reuters and Selventa Inc, holding technical positions in statistics and computational biology and several business-focused roles. His first degree is in Biochemistry from Edinburgh University, and he obtained his PhD from Kings College London (formerly Guys & St Thomas Medical School), in temporal analysis of brain development.

Ewan joined OBD in 2012 and has driven the Company’s early biomarker direction, developing statistical data pipelines, feature engineering, machine learning, and most recently leading a team of dedicated biological data scientists using BioBERT to develop a knowledge base blending existing biological knowledge with the Company’s proprietary EpiSwitch data.

Dr. Heaton is a Board-Certified Pathologist responsible for the operational oversight of the CLIA-certified Clinical Lab in Frederick, Maryland. With over three decades as a Pathologist and 13 years of medical laboratory leadership, he brings a wealth of expertise, driving excellence in diagnostic and prognostic services with our precision medicine blood tests. Dr. Heaton completed medical school at Georgetown University in 1987. He spent 20 years in the US Navy, completing his residency training in Pathology in 1992 and eventually becoming Director of Laboratory and Clinical Support Services at the National Naval Medical Center until 2007. Afterwards, he served as a Pathologist at the Shady Grove Adventist Hospital for four years. Since 2011, he’s taken on the role of Laboratory Medical Director at several Hospital Pathology labs—including Capital Choice Pathology Laboratory (2011-2016), StoneSprings Hospital Center (2015-2021), and Reston Hospital Center (2013-2021)—and Life Sciences companies, including OncoPlexDx, which became OncoOmicsDx (2012-present).